Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Probiotics vs VSL#3 / Visbiome: Probiotics has the stronger overall evidence (9 vs 6.5/10); they're alternatives for reduce inflammation — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Probiotics wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Likely helps
27 of 35 studies with measurable effects showed benefit.
Top outcomes
Verdict
Mostly mechanism / observational
Top outcomes
10-20 billion CFU
With or without food (strain-dependent), Same time daily for consistency
Capsules with multiple strains
Prevention and maintenance are DIFFERENT doses and are often conflated. Preventing the first onset of acute pouchitis used 900 billion CFU/day (1 sachet). Maintaining remission in established chronic or refractory pouchitis — where the effect size is largest — used 6 g/day, which at 5 x 10^11 viable bacteria per gram is about 3 trillion CFU/day, in both maintenance trials. As a ulcerative colitis add-on, 3.6 trillion CFU daily; the active-UC induction trial went highest at 3.6 trillion CFU TWICE daily (7.2 trillion/day), and the paediatric trial lowest at 450 billion/day weight-based
any
Refrigerated sachet of the De Simone Formulation
Redundant. VSL#3's benefits are concentrated in specific medical indications (pouchitis, ulcerative colitis) and are not additive with a consumer blend.
Do not stack. VSL#3 is used under gastroenterology supervision for defined indications, not as a general daily probiotic to layer.
2-4 weeks
4-8 weeks
4-8 weeks
First 1-2 weeks
9-12 months
12 months
8-12 weeks
n/a
Preventive Effect of Probiotics on Oral Mucositis Induced by Cancer Treatment: A Systematic Review and Meta-Analysis
International journal of molecular sciences (2022) · Meta analysis · n=708
Three trials using Lactobacilli-based probiotics reported that the incidence of oral mucositis in the probiotic group was significantly low (risk ratio [RR] = 0.84, 95% confidence interval [CI] = 0.77−0.93, p = 0.0004).
Probiotics for treating acute infectious diarrhoea
The Cochrane database of systematic reviews (2020) · Meta analysis · n=12127
Effect size was similar in the sensitivity analysis and marked heterogeneity persisted.
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
The Cochrane database of systematic reviews (2017) · Meta analysis · n=9955
A complete case analysis (i.e. participants who completed the study) among trials investigating CDAD (31 trials, 8672 participants) suggests that probiotics reduce the risk of CDAD by 60%.
Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis.
Cochrane Database Syst Rev (2019) · Meta analysis
Chronic pouchitis maintenance: 85% (34/40) maintained remission at 9-12 months vs 3% (1/36) placebo — RR 20.24 (95% CI 4.28-95.81), low certainty
Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial.
Gastroenterology (2000) · Rct · n=40
Relapse in 3/20 (15%) on the probiotic vs 20/20 (100%) on placebo, P<0.001
Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis.
Gut (2004) · Rct · n=36
Remission maintained at 1 year in 17/20 (85%) vs 1/16 (6%) placebo, p<0.0001
Based on meta-analyses showing benefits for IBS and digestive symptoms. Effect sizes varied considerably between studies with low to very low certainty of evidence. Initial GI symptoms common when starting but typically resolve within 1-2 weeks.
AI-estimated from published studies. Interpret as directional guidance.
Probiotics has a higher evidence score (9/10 vs 6.5/10) and wins in 2 of 3 categories.
For reduce inflammation, Probiotics has a higher relevance score (95 vs 42).
Redundant. VSL#3's benefits are concentrated in specific medical indications (pouchitis, ulcerative colitis) and are not additive with a consumer blend. Do not stack. VSL#3 is used under gastroenterology supervision for defined indications, not as a general daily probiotic to layer. Consult a healthcare provider for personalized advice.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Saffron, EPA omega-3, SAMe have real adjunct evidence — but these aren’t a substitute for care, and some interact dangerously.
Probiotics vs prebiotics vs synbiotics, the CFU myth, and what actually helps bloating.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.